Yahoo Finance
•Health
Health
Morphogenesis to merge with CohBar to advance late-stage cancer pipeline
77% Informative
Morphogenesis Morphogenesis Inc o combine with CohBar Inc in CohBar Inc ock transaction forming a company combining expertise and resources to advance a late-stage oncology pipeline.
The combined company will focus on advancing Morphogenesis' two technol Morphogenesis ek two overcome the major obstacles that limit the effectiveness of current immunotherapies in treating cancer.
The transaction is expected to close in Q3 of 2023. Benzinga The Nasdaq Capital Market tText__NxlGi">2023 Q3 aryF 2023 highLightText__NxlGi">Benzinga.com first ohBar Stock Doubles: Merkel Cell Carcinoma > < early 2024 ="summaryFeed_highLightText__NxlGi">Benzinga Pro < CohBar lass="summaryFeed_highLightText__NxlGi">Tuesdayapproximately 3.30 ="summaryFe CohBar hLightText__NxlGi">3.99 CohBar ="summaryFeed_highLightText__NxlGi"> approximately 15% span class="summaryFeed_highLightText__NxlGi">CWBR approximately 77% _h CohBar htText__NxlGi">CFO$15 million class="summaryFeed_highLightText__NxlGi">Dan D 2024 orn James Bianc Tampa an Florida
VR Score
74
Informative language
75
Neutral language
73
Article tone
formal
Language
English
Language complexity
57
Offensive language
not offensive
Hate speech
not hateful
Attention-grabbing headline
detected
Known propaganda techniques
not detected
Time-value
medium-lived
External references
4
Source diversity
2
Affiliate links
no affiliate links